U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.

Cover of Drugs and Lactation Database (LactMed®)

Drugs and Lactation Database (LactMed®) [Internet].

Show details

Repotrectinib

Last Revision: December 15, 2023.

Estimated reading time: 1 minute

CASRN: 1802220-02-5

image 394857851 in the ncbi pubchem database

Drug Levels and Effects

Summary of Use during Lactation

No information is available on the use of repotrectinib during breastfeeding. Because repotrectinib is 94.5% bound to plasma proteins, the amount in milk is likely to be low and oral bioavailability is less than 50%; however, the drug’s half-life is about 50 hours in adults. The manufacturer recommends that breastfeeding be discontinued during repotrectinib therapy and for 10 days after the final dose.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Substance Identification

Substance Name

Repotrectinib

CAS Registry Number

Drug Class

Breast Feeding

Lactation

Milk, Human

Antineoplastic Agents

Enzyme Inhibitors

Protein Kinase Inhibitors

Signal Transduction Inhibitors

Tyrosine Kinase Inhibitors

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Copyright Notice

Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.

Bookshelf ID: NBK598882PMID: 38163333

Views

Related information

Similar articles in PubMed

  • Review Trametinib.[Drugs and Lactation Database (...]
    Review Trametinib.
    . Drugs and Lactation Database (LactMed®). 2006
  • Review Daprodustat.[Drugs and Lactation Database (...]
    Review Daprodustat.
    . Drugs and Lactation Database (LactMed®). 2006
  • Review Sunitinib.[Drugs and Lactation Database (...]
    Review Sunitinib.
    . Drugs and Lactation Database (LactMed®). 2006
  • Review Fostamatinib.[Drugs and Lactation Database (...]
    Review Fostamatinib.
    . Drugs and Lactation Database (LactMed®). 2006
  • Review Venetoclax.[Drugs and Lactation Database (...]
    Review Venetoclax.
    . Drugs and Lactation Database (LactMed®). 2006
See reviews...See all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...